CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 6, 2014, Pages 583-585

  Roustit, M ^a,b   Fonrose, X ^b   Montani, D ^c,d   Girerd, B ^c,d   Stanke Labesque, F ^b   Gonnet, N ^b   Humbert, M ^c,d   Cracowski, J L ^a,b  

^a UNIV GRENOBLE ALPES   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT EXPORT PUMP; BOSENTAN; CYTOCHROME P450 2C9; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3;

BILE FLOW; BILE SALT EXPORT PUMP GENE; BILE SECRETION; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOCHROME P450 2C9 GENE; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG WITHDRAWAL; GENE; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; INTRAHEPATIC BILE DUCT; LIVER CELL; PHENOTYPE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3 GENE; TOXIC HEPATITIS;

ARYL HYDROCARBON HYDROXYLASES; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 84901020332     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2014.42     Document Type: Review

References (10)

1. Humbert, M. et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30, 338-344 (2007
2. Dingemanse, J. & van Giersbergen, P.L. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. 43, 1089-1115 (2004
3. Treiber, A., Schneiter, R., Hausler, S. & Stieger, B. Bosentan is a substrate of human OATP1B1 and OATP1B3: Inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35, 1400-1407 (2007
4. Fattinger, K. et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69, 223-231 (2001
5. Markova, S.M. et al. Association of CYP2C9. 2 with bosentan-induced liver injury. Clin. Pharmacol. Ther. 94, 678-686 (2013
6. Markert, C., Burhenne, J., Weiss, J., Mikus, G. & Haefeli, W.E. CYP2C9 polymorphism is not a major determinant of bosentan exposure in healthy volunteers. Clin. Pharmacol. Ther. 95, 250-251 (2013
7. Hartman, J.C., Brouwer, K., Mandagere, A., Melvin, L. & Gorczynski, R. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes. Can. J. Physiol. Pharmacol. 88, 682-691 (2010
8. Leslie, E.M., Watkins, P.B., Kim, R.B. & Brouwer, K.L. Differential inhibition of rat and human Na+dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1) by bosentan: A mechanism for species differences in hepatotoxicity. J. Pharmacol. Exp. Ther. 321, 1170-1178 (2007
9. Fouassier, L. et al. Contribution of MRP2 in alterations of canalicular bile formation by the endothelin antagonist bosentan. J. Hepatol. 37, 184-191 (2002
10. Fahrmayr, C. et al. Phase I and II metabolism and MRP2-mediated export of bosentan in a MDCKIIOATP1B1-CYP3A4-UGT1A1-MRP2 quadrupletransfected cell line. Br. J. Pharmacol. 169, 21-33 (2013